Lexicon Pharmaceuticals saw its shares bounce 8% premarket this morning on news out late last night that the FDA had approved its oral med Xermelo (telotristat…

A phase 3 trial of Accera’s Alzheimer’s disease candidate has missed its primary endpoint.

Kite Pharma’s pioneering CAR-T has shown sustained efficacy over six months, diminishing concerns about durability in the run-up to a filing for FDA approval.

The list of the 12 "priority pathogens" will help encourage and direct R&D to tackle the growing problem of antimicrobial resistance, says the…

Roche is doubling down on its anti-amyloid beta antibody crenezumab with a second phase 3 Alzheimer's trial.

Advaxis has licensed its antigen delivery technology for use in Sellas’ cancer immunotherapy.

Merck & Co.'s fast-tracked antiviral letermovir hit its main target of reducing infections in a trial involving bone marrow transplant patients and…

Pharma Two B has raised $30 million to complete a phase 3 trial of its Parkinson’s asset P2B001 and added ex-Pfizer CEO Jeff Kindler to its board.

Exonics Therapeutics has won $5 million in seed funding toward its goal of using cutting-edge new gene editing technology to help correct the majority of DMD…

Biotech